Table 3 Preclinical studies on tau vaccines
IMMUNOGEN | ANIMAL MODEL | IMPROVEMENT | EFFICACY | REFERENCE | ||
|---|---|---|---|---|---|---|
Cognitive | Sensorimotor | NFT’s | Insoluble tau | |||
Tau379–408 [pS396,404] | P301L | No change | Improved | Decreased | Decreased | [14] |
Tau 379-408 [pS396/404] | htau/PS1M146L | Improved | Improved | Reduced | Reduced | [36] |
Tau 417-426 [pS422] | Thy-Tau22 | Improved | nd. | Reduced | Reduced | [326] |
Tau393-408 [pS396/S404] (Liposome based) | P301L | nd. | Improved | No change | Reduced | [322] |
Tau379-408 [pS396/S404] | hTau X PS1 | Improved | No change | Reduced | Reduced | [37] |
hTau | Improved | No change | No change | Reduced | ||
hTau/PS1/mTau | Improved | No change | No change | Reduced | ||
Tau195-213 [pS202/T205] | DM-Tau-tg | nd. | nd. | Reduced | nd. | [30] |
Tau207-220 [pT212/S214] | nd. | nd. | Reduced | nd. | ||
Tau 224-238 [pT231] | nd. | nd. | Reduced | nd. | ||
Tau aa395-406 [pS396/404] | pR5 | nd. | nd. | Reduced | nd. | [25] |
Human paired helical filaments (PHF’s) | THY-Tau22 | nd. | nd. | Reduced | Reduced | [12] |
Tau229-237 [pT231/pS235] | P301S | nd. | nd. | nd. | nd. | [273] |
Tg2576 | ||||||
Tau199–208 [pS202/pT205] | P301S | nd. | Improved | No change | No change | [274] |
nd. | Improved | No change | No change | |||
Tau209–217 | nd. | Improved | No change | No change | ||
Tau 294-305 | SHR72 rats | nd. | Improved | Reduced | Reduced | [167] |
Tau 379-408 [pS396/404] | 3xTg-AD | No change | nd. | Reduced | Reduced | [270] |
Tau 294-305 | P301S | Improved | Reduced | Reduced | [157] | |